Last reviewed · How we verify
ANAVEX2-73
ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases.
ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases. Used for Alzheimer's disease, Parkinson's disease dementia.
At a glance
| Generic name | ANAVEX2-73 |
|---|---|
| Also known as | Blarcamesine |
| Sponsor | Anavex Life Sciences Corp. |
| Drug class | Sigma-1 receptor agonist |
| Target | Sigma-1 receptor (S1R) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug binds to and activates sigma-1 receptors, which are involved in cellular stress response and neuroprotection. This activation is thought to reduce neuroinflammation, promote neuronal survival, and restore cellular homeostasis in neurodegenerative conditions. The mechanism may also involve modulation of autophagy and mitochondrial function.
Approved indications
- Alzheimer's disease
- Parkinson's disease dementia
Common side effects
- Headache
- Nausea
- Dizziness
- Fatigue
Key clinical trials
- OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 (PHASE2, PHASE3)
- ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (PHASE2, PHASE3)
- OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 (PHASE2)
- ANAVEX2-73 for Treatment of Early Alzheimer's Disease (PHASE2, PHASE3)
- ANAVEX2-73 Study in Patients With Rett Syndrome (PHASE3)
- Study of ANAVEX2-73 in Patients With Rett Syndrome (PHASE2)
- An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease (PHASE2)
- ANAVEX2-73 Study in Parkinson's Disease Dementia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANAVEX2-73 CI brief — competitive landscape report
- ANAVEX2-73 updates RSS · CI watch RSS
- Anavex Life Sciences Corp. portfolio CI